In the specialized field of biochemical research, the cyclic RGDfK peptide has emerged as a cornerstone for those investigating cellular interactions. As a dedicated enthusiast of peptide research, I have spent significant time examining the molecular architecture of this compound. Its unique configuration, often identified by the chemical formula $C_ Cyclo(RGDfK) (CAS 161552-03-0) {27}H_{41}N_9O_7$ and a molecular weight of 603.7 g/mol, provides a fascinating look into the precision of synthetic chemistry.
Molecular Precision and Characteristics
The cyclic RGDfK is not merely a sequence; it is a meticulously engineered molecule. Known in laboratory settings as cyclo(Arg-Gly-Asp-D-Phe-Lys), it contains an Arg-Gly-Asp (RGD) sequence that is essential for its biological activity. My observations in reviewing high-purity samples MW 603.7 Da, Purity >98%.Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin (IC₅₀ = 0.94 nM). —often exceeding 98% or 99% HPLC purity—confirm that the stability of this cyclic peptide is largely due to its rigid rin Cyclo(-RGDfK) TFA | Integrin inhibitor | CAS 500577-51-5 g structure.
When discussing the chemical structure of the synthetic cyclic RGD peptide c(RGDfK), it is vital to note how the D-phenylalanine (f) and lysine (K) residues contribute Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cellsthrough the specific binding to the αvβ3 integrin on the cell surface. For research use to its selective binding properties. Cyclo(-RGDfK) is a cyclic peptide that demonstrates exceptional binding affinity, which makes it a preferred tool for researchers exploring receptor-ligand dynamics.
Research Applications and Integrin Binding
One of the most compelling aspects of this compound is that it is a well-validated ligand for targeting active to integrin αvβ3. In my experience with various biochemical assays, the precision with which this molecule interacts with specific cell surfaces is remarkable.
* αvβ3 Integrin Inhibition: Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, often showing IC50 values as low as 0.94 nM.
* Targeted Delivery: The versatility of the molecule is evident in studies where cRGDfK peptide-conjugated succinoyl-TPGS nanomicelles have been utilized, showcasing how researchers leverage its targeting capabilities.
* Cellular Interaction: 作者：G Mondal·2013·被引用次数：57—We show that a lipopeptide containing widely acclaimed αvβ3 integrin receptor selectivecyclic RGDfKligand in its head-group area can effectively deliver Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells under controlled experimental conditions, primarily through its Cyclo(RGDfK) is a RGD pipetide, potent and selective αvβ3 integrin inhibitor with Kd of 41.7 nM. Cyclo(RGDfK) shows strong inhibitory effect on the specific binding affinity.
Comparative Insights
While Cyclo(-RGDfK) remains a primary focus, there are variations such as Cyclo(-RGDfC), which serves as another high-purity integrin-binding peptide. Whether one is utilizing cyclic RGDfK or exploring the broader category of cyclic RGD peptide (cRGD), the fundamental goal remains the same: understanding how these synthetic molecules mimic natural binding motifs.
It is also worth noting that Cyclo(RGDfK) is a synthetic lipopeptide inhibitor of αvβ3 integrin, a designation that highlights its utility in complex biochemical environments. Researchers frequently cite that it effectively targets tumor microvessels and cancer cells, making it a staple in advanced laboratory protocols.
Concluding Observations
As someone 作者：H Kulhari·2015·被引用次数：69—We report the synthesis ofcRGDfK peptide-conjugated succinoyl-TPGS(tocopheryl polyethylene glycol succinate) nanomicelles for targeted delivery of DTX. deeply interested in the evolution of peptide tools, I find that the Cyclic RGDFK peptide continues to offer reliable performance in qualitative studies. Whether it is identified as a cyclic RGD tumor-targeting peptide or simply a RGD peptide, its role in modern research is undeniable. The reproducibility of results—provided the compound is sourced with high purity—is a testament to the rigorous standards now applied to the synthesis of these cyclic peptides.
By maintaining a focus on the structural integrity and the specific binding kinetics of RGDfK, researchers can continue to push the boundaries of what is possible in biochemical investigation, ensuring that every experiment is grounded in verifiable, high-quality data.